EMA starts rolling review for Eli Lilly's Covid-19 treatment
Two new antibodies for Covid-19 have been placed under rolling review by the EMA. This will ensure faster approval in case the drug reaches the point of submitting an application.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
The European Medicines Agency (EMA) has started reviewing the preliminary data on two Eli Lilly treatments for Covid-19, writes the Danish Medicines Agency in a press announcement.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Denmark suspends Astrazeneca vaccinations
For subscribers
The EMA starts rolling review of Russian vaccine
For subscribers
.jpg)
.jpg&w=384&q=75)
